<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Psyence Group Inc — News on 6ix</title>
<link>https://6ix.com/company/psyence-group-inc</link>
<description>Latest news and press releases for Psyence Group Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 23:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/psyence-group-inc" rel="self" type="application/rss+xml" />
<item>
<title>Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-provides-update-on-proposed-amalgamation-with-goldcoast-resource-corp</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-provides-update-on-proposed-amalgamation-with-goldcoast-resource-corp</guid>
<pubDate>Tue, 17 Mar 2026 23:00:00 GMT</pubDate>
<description>GoldCoast Closes First Tranche of Private Placement TORONTO, ON / ACCESS Newswire / March 17, 2026 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that GoldCoast Resource Corp. ("GoldCoast"), the private company with which Psyence ...</description>
</item>
<item>
<title>Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-into-amending-agreement-to-extend-amalgamation-timeline-with-goldcoast-resource-corp</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-into-amending-agreement-to-extend-amalgamation-timeline-with-goldcoast-resource-corp</guid>
<pubDate>Tue, 24 Feb 2026 11:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / February 24, 2026 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that it has entered into an amending agreement (the "Amending Agreement") dated February 24, 2026 with GoldCoast Resource Corp. ...</description>
</item>
<item>
<title>Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-groups-rto-target-goldcoast-145000047</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-groups-rto-target-goldcoast-145000047</guid>
<pubDate>Tue, 27 Jan 2026 14:50:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / January 27, 2026 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast"), has been granted a series of ten contiguous offshore ...</description>
</item>
<item>
<title>Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp.</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-amalgamation-182000641</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-amalgamation-182000641</guid>
<pubDate>Mon, 24 Nov 2025 18:20:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / November 24, 2025 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has entered into a definitive amalgamation agreement (the ...</description>
</item>
<item>
<title>Psyence Group Inc. Announces RSU Grants</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-rsu-200500553</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-rsu-200500553</guid>
<pubDate>Fri, 17 Oct 2025 20:05:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / October 17, 2025 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") to certain executives, officers, directors and consultants ...</description>
</item>
<item>
<title>Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp.</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-letter-152300153</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-enters-letter-152300153</guid>
<pubDate>Fri, 22 Aug 2025 15:23:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / August 22, 2025 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the issued and outstanding securities and securities convertible ...</description>
</item>
<item>
<title>Psyence Group Inc. Closes Second Tranche of Non‑Brokered Private Placement for Remaining Proceeds</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-closes-second-210000166</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-closes-second-210000166</guid>
<pubDate>Mon, 07 Jul 2025 21:00:00 GMT</pubDate>
<description>TORONTO, ON / ACCESS Newswire / July 7, 2025 /Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of its previously announced non‑brokered private placement ...</description>
</item>
<item>
<title>PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-previously-210000972</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-previously-210000972</guid>
<pubDate>Wed, 25 Jun 2025 21:00:00 GMT</pubDate>
<description>TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tran</description>
</item>
<item>
<title>PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-offering-213600082</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-inc-announces-offering-213600082</guid>
<pubDate>Wed, 18 Jun 2025 21:36:00 GMT</pubDate>
<description>TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payab</description>
</item>
<item>
<title>Psyence Group Announces Share Consolidation</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-group-announces-share-consolidation-133900713</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-group-announces-share-consolidation-133900713</guid>
<pubDate>Thu, 17 Apr 2025 13:39:00 GMT</pubDate>
<description>TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the "Share Consolidation"), effective April 23, 2025 with a record date of April 23, 2025 (the "Record Date"). As a result of the Share Consolidation, the issued and outstanding Common S</description>
</item>
<item>
<title>Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-groups-nasdaq-listed-associate-144700681</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-groups-nasdaq-listed-associate-144700681</guid>
<pubDate>Tue, 25 Mar 2025 14:47:00 GMT</pubDate>
<description>TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. According to a news release issued by PBM, Dr. Stein is the Professor and Chair of the Dept of Psych</description>
</item>
<item>
<title>Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board</title>
<link>https://6ix.com/company/psyence-group-inc/news/psyence-groups-nasdaq-listed-associate-151800658</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-group-inc/news/psyence-groups-nasdaq-listed-associate-151800658</guid>
<pubDate>Mon, 10 Mar 2025 15:18:00 GMT</pubDate>
<description>Psyence Group settles Debt for SharesTORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). According to a news release issued by PBM, Dr. Garcia-Romeu is a leading psychedelics researche</description>
</item>
</channel>
</rss>